![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
TD-6450, a Heterodimeric HCV NS5A Inhibitor with a High Barrier to Resistance and Pan-Genotypic Potency
|
|
|
Reported by Jules Levin
HEP DART 2013:
Frontiers in Drug Development for Viral Hepatitis.
December 8-12, 2013 · Big Island, Hawaii, USA.
J Budman, CE Waltman, W Krey-Epstein, R Chang, S Smith, A Amrite, M Mammen, M McKinnell Theravance, Inc., South San Francisco, CA, USA
![AASLD1.gif](../images/121613/121613-6/AASLD1.gif)
![AASLD2.gif](../images/121613/121613-6/AASLD2.gif)
![AASLD3.gif](../images/121613/121613-6/AASLD3.gif)
![AASLD4.gif](../images/121613/121613-6/AASLD4.gif)
![AASLD5.gif](../images/121613/121613-6/AASLD5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|